Overview
Chronic hyperplastic candidosis (CHC), also known as chronic atrophic candidiasis or chronic hyperplastic laryngitis, is a persistent inflammatory condition primarily affecting the oral mucosa, particularly the tongue. This condition is characterized by the overgrowth of Candida albicans and other Candida species, leading to significant tissue changes and chronic symptoms. The pathophysiology involves complex interactions between the fungal pathogen, host immune response, and environmental factors. Epidemiological studies highlight that smoking, hyposalivation, and loss of vertical dimension of occlusion are significant risk factors for the development of CHC. Clinically, patients often present with symptoms such as persistent oral discomfort, altered taste sensation, and visible mucosal changes. Accurate diagnosis relies on a combination of direct microscopic examination, culture methods, and immunohistochemical analysis, while management strategies focus on antifungal therapy and addressing underlying predisposing factors.
Pathophysiology
The pathophysiology of chronic hyperplastic candidosis (CHC) involves intricate interactions between Candida albicans and the host immune system, leading to persistent inflammation and tissue alterations. Despite extensive studies, specific genotypes uniquely associated with CHC have not been identified through PCR fingerprinting of C. albicans isolates from CHC patients compared to those from other oral conditions [PMID:11682531]. However, the presence of 1B12 positive hyphal structures in formalin-fixed paraffin-embedded (FFPE) tissue blocks strongly suggests that C. albicans plays a pivotal role in CHC by infiltrating and disrupting tissue architecture [PMID:10193330]. This infiltration likely triggers a robust immune response, as evidenced by the widespread distribution of CD1a-positive Langerhans cells throughout the epithelial layers and lamina propria, indicating active dendritic cell recruitment and maturation [PMID:17559493]. Additionally, mast cells exhibit signs of active engagement through degranulation, contributing soluble RANKL, which may further modulate the inflammatory milieu [PMID:17559493].
Immunocytochemical analyses reveal a dominant presence of T-lymphocytes (53.9%) and a notable infiltration of IgA-containing cells (36.7%) in CHC lesions, underscoring the importance of both cellular and humoral immune responses in this condition [PMID:9049907]. The prevalence of pseudohyphae, particularly in the retrocommissural and lateral borders of the tongue in patients with compromised oral conditions such as loss of vertical dimension of occlusion, further supports the role of Candida morphogenesis in disease progression [PMID:27659076]. Despite these findings, phenotypic analyses of C. albicans isolates from CHC patients do not show significant differences in carbohydrate assimilation, chemical sensitivity, or serotype distribution compared to non-CHC isolates, suggesting that virulence factors may not be uniquely distinct but rather context-dependent [PMID:10670572].
Epidemiology
Chronic hyperplastic candidosis (CHC) exhibits notable epidemiological associations that highlight key risk factors for its development. Studies have consistently shown that the presence of Candida species is significantly more prevalent in individuals who smoke, experience hyposalivation, or have a loss of vertical dimension of occlusion compared to controls [PMID:27659076]. These factors create an environment conducive to Candida overgrowth, likely due to reduced local immune defenses and altered mucosal conditions. Smoking, in particular, impairs mucosal integrity and reduces the effectiveness of local immune responses, making the oral mucosa more susceptible to fungal colonization and invasion [PMID:27659076]. Hyposalivation further exacerbates this issue by diminishing the protective effects of saliva, which normally helps control microbial populations in the oral cavity. Therefore, preventive strategies targeting smoking cessation, maintaining adequate hydration, and addressing occlusal issues may play crucial roles in reducing the incidence of CHC.
Clinical Presentation
Patients with chronic hyperplastic candidosis (CHC) typically present with a constellation of symptoms and characteristic mucosal changes that are critical for clinical diagnosis. Common clinical manifestations include persistent oral discomfort, such as burning sensations or soreness, which can significantly impact quality of life [PMID:27659076]. Visible alterations in the oral mucosa are often observed, particularly on the tongue, where erythematous, atrophic, or hyperplastic lesions may appear. These lesions frequently involve the retrocommissural and lateral borders, areas prone to reduced salivary flow and mechanical irritation [PMID:27659076]. Patients may also report altered taste sensation, contributing to difficulties in eating and enjoyment of food. In some cases, there might be associated halitosis (bad breath) due to chronic inflammation and microbial overgrowth. The presence of pseudohyphae, as identified through direct microscopic examination, can serve as a diagnostic clue, especially in high-risk individuals [PMID:27659076]. Clinicians should be vigilant for these clinical signs, particularly in patients with known risk factors such as smoking, hyposalivation, or dental occlusal issues, to facilitate early and accurate diagnosis.
Diagnosis
Accurate diagnosis of chronic hyperplastic candidosis (CHC) is essential for effective management and relies on a multifaceted approach combining clinical examination with laboratory techniques. Direct microscopic examination remains a cornerstone diagnostic tool, where the identification of pseudohyphae and yeast forms within mucosal scrapings is highly indicative of Candida infection [PMID:27659076]. Culture methods are also crucial, as they not only confirm the presence of Candida species but also allow for speciation and assessment of antifungal susceptibility patterns. However, precise identification is paramount, as atypical isolates initially identified as C. albicans can sometimes be Candida dubliniensis, necessitating advanced molecular techniques such as PCR for accurate differentiation [PMID:11682531]. Immunohistochemical analysis using monoclonal antibodies like 1B12 has proven valuable in detecting C. albicans hyphae within lesional tissue, offering a robust confirmatory diagnostic approach [PMID:10193330]. Additionally, optimized antigen-retrieval techniques, such as pepsin digestion, enhance the visualization of CD1a-positive Langerhans cells and mast cell degranulation, which can serve as additional diagnostic markers [PMID:17559493]. While trends towards increased boric acid resistance in CHC isolates warrant further investigation, current diagnostic practices should prioritize direct microscopic findings, culture results, and immunohistochemical evidence to ensure comprehensive evaluation [PMID:10670572]. Biopsy material showing significant infiltration of T-lymphocytes and IgA-containing cells further supports the diagnosis by highlighting the immune response characteristic of CHC [PMID:9049907].
Management
The management of chronic hyperplastic candidosis (CHC) involves a multifaceted approach aimed at eradicating the fungal infection and addressing underlying predisposing factors to prevent recurrence. Antifungal therapy is typically the cornerstone of treatment, with various agents such as topical antifungals (e.g., nystatin, clotrimazole) and systemic options (e.g., fluconazole) being employed based on the severity and extent of the infection [PMID:11682531]. Despite aggressive antifungal interventions, persistent strains of C. albicans have been observed in some patients for up to seven years, highlighting the challenge of achieving long-term eradication [PMID:11682531]. Therefore, continuous monitoring and periodic reassessment are crucial to manage recurrent episodes effectively.
In addition to pharmacological treatments, preventive strategies targeting modifiable risk factors are essential. Given the strong associations with smoking, hyposalivation, and occlusal issues, interventions such as smoking cessation programs, maintaining adequate hydration, and addressing dental occlusal problems can significantly reduce the risk of CHC development and recurrence [PMID:27659076]. Enhancing mucosal defense mechanisms, particularly through approaches that boost IgA production, may also offer therapeutic benefits by strengthening the local immune response against Candida overgrowth [PMID:9049907]. Regular follow-up visits and patient education on oral hygiene practices are integral to managing CHC, ensuring that patients are aware of signs of recurrence and understand the importance of adhering to prescribed treatments and preventive measures.
Key Recommendations
References
1 Bartie KL, Williams DW, Wilson MJ, Potts AJ, Lewis MA. PCR fingerprinting of Candida albicans associated with chronic hyperplastic candidosis and other oral conditions. Journal of clinical microbiology 2001. link 2 Williams DW, Jones HS, Allison RT, Potts AJ, Lewis MA. Immunocytochemical detection of Candida albicans in formalin fixed, paraffin embedded material. Journal of clinical pathology 1998. link 3 Arruda C, Artico G, Freitas R, Filho A, Migliari D. Prevalence of Candida spp. in Healthy Oral Mucosa Surfaces with Higher Incidence of Chronic Hyperplastic Candidosis. The journal of contemporary dental practice 2016. link 4 Ali A, Rautemaa R, Hietanen J, Beklen A, Konttinen Y. A possible CD1a Langerhans cell-mast cell interaction in chronic hyperplastic candidosis. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2007. link 5 Williams DW, Wilson MJ, Potts AJC, Lewis MAO. Phenotypic characterisation of Candida albicans isolated from chronic hyperplastic candidosis. Journal of medical microbiology 2000. link 6 Williams DW, Potts AJ, Wilson MJ, Matthews JB, Lewis MA. Characterisation of the inflammatory cell infiltrate in chronic hyperplastic candidosis of the oral mucosa. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 1997. link